312P - Elevated serum CA125 predicts recurrence in patients with completely resected ovarian clear cell carcinoma

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Ovarian Cancer
Biomarkers
Surgery and/or Radiotherapy of Cancer
Presenter Takahiro Ebata
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors T. Ebata1, M. Yunokawa2, S. Bun3, E. Noguchi4, A. Shimomura4, T. Shimoi4, K. Yonemori4, C. Shimizu4, Y. Fujiwara4, T. Kato5, K. Tamura4
  • 1Medical Oncology, Chiba University, School of Medicine, 260-8677 - Chiba/JP
  • 2Breast And Medical Oncology, National Cancer Center Hospital, Tokyo/JP
  • 3Pharmacy, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 5Gynecology, National Cancer Center Hospital, 104-0045 - Tokyo/JP

Abstract

Background

The Gynecological Cancer Intergroup has recommended that serum CA125, which is a good predictive marker for recurrence, be included in the criteria for defining response and progression of ovarian carcinoma. However, the criteria were developed on the basis of patients with serous adenocarcinoma. To assess the optimal criteria for patients with clear cell carcinoma, we investigated elevated serum CA125 and recurrence in patients with ovarian clear cell carcinoma.

Methods

We retrospectively investigated the medical records of patients with ovarian clear cell carcinoma at our hospital between June 1997 and December 2014. Patients with optimally resected and histologically confirmed clear cell carcinoma in our hospital whose serum CA125 level was higher than 35 U/mL before treatment and lower after operation or adjuvant chemotherapy were included in this study. We calculated the sensitivity, specificity, positive and negative predictive values, and time between elevation and radiological recurrence.

Results

One hundred and thirty nine patients were diagnosed with ovarian clear cell carcinoma during this period. Of these, 55 patients were eligible for the study, and 16 events [A1] [A2] occurred. The sensitivity and specificity of elevated serum CA125 level for predicting recurrence were 68.8% and 97.4%. The positive and negative predictive values were 91.7% and 88.4%. The median time from CA125 elevation to recurrence was 28 days (95% confidence interval: 0–51 days).

Conclusions

A CA125 level above 35 U/mL was highly specific for predicting recurrence. We should consider radiological examinations for patients with clear cell carcinoma and CA125 levels over 35 U/mL.

Clinical trial indentification

Legal entity responsible for the study

National Cancer Center Hospital

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.